(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 38.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.88%.
Omniab's revenue in 2025 is $26,391,000.On average, 5 Wall Street analysts forecast OABI's revenue for 2025 to be $5,807,516,445, with the lowest OABI revenue forecast at $3,273,216,419, and the highest OABI revenue forecast at $8,427,310,929. On average, 4 Wall Street analysts forecast OABI's revenue for 2026 to be $7,590,075,908, with the lowest OABI revenue forecast at $3,761,756,183, and the highest OABI revenue forecast at $10,747,874,808.
In 2027, OABI is forecast to generate $8,364,167,165 in revenue, with the lowest revenue forecast at $4,372,430,888 and the highest revenue forecast at $12,170,746,871.